Get started
Author

James Motyka

Observed names: J Motyka, James D Motyka, James D. Motyka
Observed institution: National Pharmaceutical Council
ORCID: 0009-0006-9216-0141
Observed ORCID: 0009-0006-9216-0141
OpenAlex ID: A5095367814
Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act
2024 · Julie A. Patterson, James Motyka, et al. · Therapeutic Innovation & Regulatory Science · 9
PDF
Drug Coverage Policies And Clinical Guidelines Alignment: Most Coverage Decisions Include Additional Restrictions
2025 · Julia A. Rucker, Molly T. Beinfeld, et al. · Health Affairs · 6
How The IRA Could Delay Pharmaceutical Launches, Reduce Indications, And Chill Evidence Generation
2023 · John Michael O’Brien, James Motyka, et al. · Forefront Group · 6
US Drug Pricing Patterns Before Loss of Exclusivity
2025 · Ching-Hsuan Lin, Jonathan D. Campbell, et al. · Value in Health · 4
The Association of 340B Program Drug Margins with Covered Entity Characteristics
2025 · Robert J. Nordyke, James Motyka, et al. · INQUIRY The Journal of Health Care Organization Provision and Financing · 3
The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs
2025 · Robert J. Nordyke, Julie A. Patterson, et al. · Value in Health · 2
PDF
The Association of the 340B Program with Affordable Care Act (ACA) Premiums: A Longitudinal Analysis from 2018 to 2022
2025 · Neal Masia, James D. Motyka, et al. · INQUIRY The Journal of Health Care Organization Provision and Financing · 2
The timeliness of health plan drug coverage policy changes to FDA label revisions
2026 · Daniel E Enright, Molly T Beinfeld, et al. · Health Affairs Scholar · 1
HPR13 Are Commercial Insurance Premiums Associated With the 340B Drug Pricing Program?
2025 · Neal Masia, James Motyka, et al. · Value in Health
HPR45 The Cost of 340B to States
2025 · Chuan Sun, Shanyue Zeng, et al. · Value in Health
HPR147 Ongoing Accelerated Approval Trends and What It Means for Patients
2025 · James Motyka, Rayan K. Salih, et al. · Value in Health
HPR11 Revenue-Sharing or Revenue Lost? The Hidden Costs of 340B to Employers
2024 · C Sun, R Martin, et al. · Value in Health
PDF
HPR132 Employer Perspectives on Alternative Funding Programs
2024 · L Huff, J Motyka, et al. · Value in Health
PDF
Works count: 13
Citation count: 33
H-index: 4
I10-index:
Year
Topic
Type